Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Eur Rev Med Pharmacol Sci ; 26(23): 8935-8944, 2022 12.
Article in English | MEDLINE | ID: mdl-36524513

ABSTRACT

OBJECTIVE: Hematopoietic stem cell transplantation (HSCT) is an important curative treatment option for many hematologic diseases. Sleep disorders in patients with HSCT are a significant but often overlooked health problem. Therefore, this study aims to determine the frequency of sleep disorders in HSCT patients and to compare and evaluate the data before and after transplantation between autologous and allogeneic HSCT patient groups. PATIENTS AND METHODS: Patients who were referred to the Bone Marrow Transplantation Centre Clinic at Medicana International Istanbul Hospital by other centres and those who were suitable for HSCT treatment according to evaluations were included in the study. The patients underwent allogeneic and autologous HSCT. The Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI) were applied to both groups before transplantation and on the 7th and 100th days after transplantation. RESULTS: The PSQI total and sub-scale scores, ESS scores and ISI scores on the 7th and 100th days after transplantation were statistically significantly lower than the scores before transplantation. CONCLUSIONS: Sleep disorders were significantly reduced in patients after HSCT. Moreover, the scores in the seven subscales of the PSQI statistically significantly decreased on the 7th and 100th days after transplantation, and sleep statistically improved and showed great improvement on the 100th day after transplantation. We believe that early detection and treatment of sleep disorders may be beneficial for this group of patients to improve their quality of life and response to treatment.


Subject(s)
Hematopoietic Stem Cell Transplantation , Sleep Wake Disorders , Humans , Quality of Life , Sleep Wake Disorders/therapy , Sleep , Hematopoietic Stem Cell Transplantation/adverse effects , Transplantation, Autologous
2.
Eur Rev Med Pharmacol Sci ; 26(16): 5718-5728, 2022 08.
Article in English | MEDLINE | ID: mdl-36066145

ABSTRACT

OBJECTIVE: The systemic immune inflammation (SII) index has been an excellent prognostic indicator in patients with acute ischemic stroke (AIS). In this study, we assessed the utility of the SII in predicting the prognosis and reperfusion status of patients with AIS who underwent endovascular treatment (EVT). PATIENTS AND METHODS: 123 consecutive AIS patients were enrolled in our study. The receiver-operating characteristics (ROC) curve was used to determine the cut-off value of SII for predicting unsuccessful cerebral reperfusion. Multivariate logistic regression analysis analyzed the association between SII and unsuccessful reperfusion rate after EVT. RESULTS: The median value of SII was significantly higher in patients with unsuccessful reperfusion compared to patients with successful reperfusion [2,029 (1,217-2,771) vs. 1,172 (680-2,145) respectively, p=0.003)]. A ROC curve analysis showed that the best cut-off value of SII for predicting unsuccessful reperfusion status was 1,690, with sensitivity and specificity of 71% and 69%, respectively. The area under the curve (AUC) was 0.673 (95% CI; 0.552-0.793). Multivariate analysis demonstrated that SII ≥ 1,690 value was an independent predictor of unsuccessful cerebral reperfusion and unfavorable clinical outcome after EVT (Hazard ratio - H.R.=3.713, 95% CI: 1.281-10.76, p=0.016, HR=2.28, 95% CI: 1.06-4.88, p=0.035, respectively). CONCLUSIONS: We suggested that SII is a potential indicator to predict the unsuccessful cerebral reperfusion and unfavorable clinical outcome for patients with AIS undergoing EVT.


Subject(s)
Ischemic Stroke , Humans , Inflammation , Ischemic Stroke/diagnosis , Ischemic Stroke/surgery , Prognosis , Proportional Hazards Models , Reperfusion , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL